Vulval Lichen Sclerosus Associated With Immune Checkpoint Inhibitor Therapy: A Case Series of 11 Patients
There have only been a limited number of case reports that have described vulval lichen sclerosus in patients receiving immune checkpoint inhibitor (ICI) therapy. We describe 11 cases of vulval lichen sclerosus in patients with melanoma treated with ICIs, and in nine of these cases, the lichen sclerosus symptoms began after ICI commencement. This represents the largest reported series to date and highlights the need for clinician awareness of this potential immune-related adverse effect.
Authors
- Thevaki Wain (ORCID: https://orcid.org/0000-0002-6769-9675)
- Lauren E. Haydu (ORCID: https://orcid.org/0000-0002-6360-0199)
- Sophie Walter (ORCID: https://orcid.org/0000-0001-6003-8914)
- Amanda Glanz (ORCID: https://orcid.org/0000-0002-3356-1643)
- Diona L. Damian (ORCID: https://orcid.org/0000-0002-2857-1775)
- Linda K. Martin (ORCID: https://orcid.org/0000-0001-9519-7077)
- Matteo Salvatore Carlino (ORCID: https://orcid.org/0000-0002-7861-4104)
- Francesca Watts
- Raquel Ruiz Araujo
- Georgina V. Long
Institutions
- The University of Sydney (AU)
- Mater Health Services (AU)
- Royal Prince Alfred Hospital (AU)
- Royal North Shore Hospital (AU)
- Blacktown & Mount Druitt Hospital (AU)
- Westmead Hospital (AU)
- UNSW Sydney (AU)
- Melanoma Institute Australia (AU)
- Mater Private Hospital (AU)
Publication Details
- Journal
- Australasian Journal of Dermatology
- Published
- 2026-02-02
- DOI
- https://doi.org/10.1111/ajd.70058
- Primary Topic
- Genital Health and Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Warwick
- University of New South Wales
- University of Sydney
- Melanoma Institute Australia
- National Health and Medical Research Council